CLPT logo

ClearPoint Neuro, Inc. Stock Price

NasdaqCM:CLPT Community·US$265.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 21 Fair Values set on narratives written by author

CLPT Share Price Performance

US$8.68
-2.79 (-24.32%)
US$25.00
Fair Value
US$8.68
-2.79 (-24.32%)
65.3% undervalued intrinsic discount
US$25.00
Fair Value
Price US$8.68
AnalystConsensusTarget US$25.00
AnalystHighTarget US$30.00
AnalystLowTarget US$20.00

CLPT Community Narratives

AnalystConsensusTarget·
Fair Value US$25 65.3% undervalued intrinsic discount

Minimally Invasive Neurosurgery Will Improve Global Clinical Outcomes

0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
AnalystHighTarget·
Fair Value US$30 71.1% undervalued intrinsic discount

IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystLowTarget·
Fair Value US$20 56.6% undervalued intrinsic discount

Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$20
56.6% undervalued intrinsic discount
Profit Margin
12.86%
Future PE
88.14x
Price in 2029
US$25.31
US$30
71.1% undervalued intrinsic discount
Profit Margin
12.56%
Future PE
74.06x
Price in 2029
US$37.79

Trending Discussion

Updated Narratives

CLPT logo

CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Platform Adoption

Fair Value: US$25 65.3% undervalued intrinsic discount
14 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CLPT logo

Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders

Fair Value: US$20 56.6% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CLPT logo

IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential

Fair Value: US$30 71.1% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with limited growth.

2 Risks
1 Reward

ClearPoint Neuro, Inc. Key Details

US$37.0m

Revenue

US$14.3m

Cost of Revenue

US$22.7m

Gross Profit

US$48.2m

Other Expenses

-US$25.5m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.86
61.38%
-69.08%
175.1%
View Full Analysis

About CLPT

Founded
1998
Employees
172
CEO
Joseph Burnett
WebsiteView website
www.clearpointneuro.com

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.